Pathos AI Acquires Majority Stake in DeuterOncology to Advance AI-Identified MET Inhibitor DO-2
核心洞察
Pathos AI (搜索) acquired a majority stake in DeuterOncology (搜索) through its AI-powered Foundry platform, marking one of the first clinical-stage oncology acquisitions sourced and executed entirely through artificial intelligence.
The acquired asset DO-2 is a third-generation MET kinase inhibitor (搜索) that demonstrated 100% tumor shrinkage in all evaluable MET exon 14 skipping NSCLC patients with only 5% peripheral edema rate versus 62-82% for competitors.
The Foundry platform systematically identified DO-2 from large-scale clinical datasets in late 2025, completing the entire evaluation and acquisition process in a fraction of traditional due diligence time.
Pathos AI (搜索) announced the acquisition of a majority stake in Belgium-based DeuterOncology (搜索), developer of DO-2, a third-generation MET kinase inhibitor (搜索) for patients with MET-altered cancers (搜索). The transaction represents a landmark achievement as one of the first clinical-stage oncology acquisitions systematically identified, evaluated, and executed through an AI-powered drug development platform.
AI-Driven Asset Discovery
The acquisition was orchestrated through Pathos AI (搜索)'s Foundry platform, which continuously analyzes large-scale clinical and scientific datasets including conference proceedings, regulatory filings, published trial data, and proprietary real-world evidence. In late 2025, Foundry flagged DO-2 as a top-ranked candidate based on its mechanism of action, pharmacokinetic profile, early clinical signal, and probability of success relative to the competitive landscape.
"The traditional approach to finding clinical assets is built on relationships, conference presence, and reputation. Foundry is built on data," said Iker Huerga, CEO of Pathos AI (搜索). "It evaluates every asset purely on its merits — mechanism, pharmacokinetics, clinical signal, and probability of success. DO-2 scored at the top of our models. Ultimately, the best molecule wins."
The entire process from initial identification to management's final investment decision was completed in a fraction of the time required by traditional due diligence methods.
Addressing MET Inhibitor Limitations
MET inhibitors represent an established therapeutic class for MET-altered Non-Small Cell Lung Cancer (搜索) (NSCLC), but current approved agents face significant tolerability challenges with peripheral edema rates of 62-82%, frequently requiring dose reductions and treatment discontinuation.
DO-2's deuterated structure and "fast on / fast off" binding kinetics deliver potent MET inhibition for 8-12 hours per day. This design provides sufficient target coverage for robust antitumor activity without causing the sustained endothelial damage that drives chronic edema.
Clinical Performance Data
In a Phase 1 study involving 28 patients, DO-2 demonstrated remarkable efficacy and safety outcomes. The drug achieved 100% tumor shrinkage in all evaluable MET exon 14 skipping NSCLC patients (10/10). The safety profile showed zero Grade 4 adverse events and a peripheral edema rate of just 5%, representing a substantial improvement over the 62-82% rates observed with competing therapies.
The drug is administered as a convenient 60 mg once-daily oral dose, with patent exclusivity extending to December 2040.
"Pathos's ability to recognize the potential of this program through rigorous, data-driven analysis is exactly the kind of conviction that will bring DO-2 to the patients who need it," said Dr. Timothy Perera, Founder and CEO of DeuterOncology (搜索).
Platform-Driven Development
The Foundry platform extends beyond asset identification to comprehensive drug development support. Composed of thousands of AI agents working in parallel and powered by the Pathos Oncology Foundation Model, the system identifies undervalued assets and proposes portfolio decisions for management while continuously analyzing emerging data throughout the development lifecycle.
The same system that identified DO-2 will now guide its clinical development. DO-2 represents one of four major portfolio decisions made through Foundry in the first quarter of 2026 alone.
"We are not interested in process automation. We are redesigning drug development from first principles," said Huerga. "DO-2 is proof that the system works."
Company Background
DeuterOncology (搜索) has completed Phase 1 dose escalation studies across eight clinical sites in the Netherlands, Belgium, and France. Pathos AI (搜索) maintains an active pipeline including clinical-stage programs in metastatic castration-resistant prostate cancer (搜索) (mCRPC) and MET-altered NSCLC, with established partnerships including AstraZeneca and Tempus AI.